Food Exec Brief: Margin Preservation’s Urgent Mandate, AI’s Workforce Revolution, and Alternative Protein’s Commercial Breakthrough
Welcome to this week’s Food Exec Brief, your strategic intelligence roundup covering the industry’s desperate fight to preserve margins amid relentless cost pressures, AI and robotics emerging as the only viable solution to catastrophic labor shortages, and alternative proteins finally achieving commercial viability as manufacturers race to capture the $290 billion opportunity reshaping protein markets. […]
Long-term GLP-1 use trims medical cost growth: Aon
Long-term GLP-1 use slows medical cost growth, according to findings published Jan. 13 from professional services firm Aon. The firm analyzed 192,000 GLP-1 users from July 2022 to March 2025, comparing outcomes to non-users, through commercial medical and pharmacy claims data. This research builds off 2025 analyses. “These results provide employers a much clearer view […]
Taco Bell rolls out new ‘luxe’ $3 value menu as fans debate the tradeoffs
A major fast-food chain is revamping its value menu as diners grow more price-conscious — and the early reaction is split. Taco Bell is expanding its value offerings with the launch of its new Luxe Value Menu, featuring 10 items priced at $3 or less. The menu, which debuts nationwide Jan. 22 and combines five […]
Summary of JP Morgan Conference in Obesity and Metabolic Diseases
Here’s a summary of the major announcements and trends from the 44th Annual JP Morgan Healthcare Conference in San Francisco (January 12–15, 2026) specifically in the areas of obesity, weight-loss drugs, metabolic disease, and adjacent therapies: (BioSpace) Fierce Biotechscanx.tradeReutersReutersAd Hoc News 🧠 1. Shift Toward Oral Obesity DrugsA major theme at JPM 2026 was the […]
Day 1 @ JP Morgan in Obesity Drugs and Therapies
JP Morgan 2026: Obesity & GLP-1 Therapies Take Center StageWhat the Latest Deals and Data Mean for the Future of Metabolic MedicineThe J.P. Morgan Healthcare Conference once again served as the bellwether for where biotech and pharma are headed—and in 2026, GLP-1 and obesity therapeutics dominated the conversation.From next-generation incretin drugs to RNA-based obesity targets […]
Day 2 @ JP Morgan in Obesity Drugs and Therapies
Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments Fierce PharmaPharmaceutical TechnologyReutersFierce BiotechPharmaceutical Technology 🧪 New & Emerging TherapiesAmgen’s MariTide weight-loss programAmgen touted positive data on its experimental obesity drug MariTide, showing the therapy helped trial participants maintain significant […]
Sunlight.com Survey: 4 in 10 Overweight Americans Say They’ll Try a GLP-1 Pill in 2026
Most current GLP-1 users are interested in switching to an oral form KIRKLAND, Wash., Jan. 16, 2026 /PRNewswire/ — A new survey from Sunlight.com finds strong interest in GLP-1 medications in pill form among overweight Americans. The January 2026 survey of 2,000 overweight U.S. adults…
#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026
SAN FRANCISCO — Throughout his 53 meetings at this year’s JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone’s minds. “We’re going to put a cup in the middle of …
Resmed highlights AI-driven CPAP tech, competitive bidding win and GLP-1 insights at J.P. Morgan Hea – HME News
Resmed highlights AI-driven CPAP tech, competitive bidding win and GLP-1 insights at J.P. Morgan Hea HME News
Signal Boost 2026
Signal Boost 2026 Second week of January. Year of the Horse. Back in the saddle. As I point my GPS toward a familiar constellation of pursuits, here’s a topline look at what I’m watching and where I think the music business is headed in 2026. These aren’t predictions, they’re signals. More from Spin: Bruno Mars […]